333 results about "Granulocyte" patented technology

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

The invention discloses a strain of Lactobacillus paracasei SX-G1520 and an application of the Lactobacillus paracasei SX-G1520 in preparation of a lipid-lowering, anti-inflammatory and / or antioxidant product, the preservation number of the Lactobacillus paracasei SX-G1520 is CCTCC (China Center for Type Culture Collection) No: M 2025032, and the Lactobacillus paracasei SX-G1520 is preserved in the China Center for Type Culture Collection on January 6, 2025. The Lactobacillus paracasei SX-G1520 strain provided by the invention has lipid-lowering and antioxidant functions, significantly reduces the content of intestinal neutrophils of a zebra fish inflammatory bowel disease model, shows a significant effect on relieving intestinal inflammation, is good in safety, and has good application prospects. And a new technical choice is provided for developing probiotic preparations for regulating fat metabolism, resisting oxidative stress and preventing and treating inflammatory bowel diseases.

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention relates to the technical field of disease curative effect evaluation, and discloses a method for evaluating the curative effect of granulocyte deficiency accompanying fever after hematologic tumor chemotherapy based on machine learning, and the method comprises the steps: S1, collecting and preprocessing multi-center medical data, the data comprising structured clinical data and multi-modal unstructured data; s2, a curative effect prediction model is constructed based on a graph neural network, and a central moment constraint-based graph federal learning training model is adopted, wherein a patient graph is constructed as an original graph and an enhanced graph is generated; respectively processing the original image and the enhanced image through a two-channel image convolutional neural network, and extracting a high-order representation vector; constructing an enhanced perception loss function based on the high-order representation vectors of the original image and the enhanced image; combining a federated learning framework with multi-center data to train a model; and S3, predicting a curative effect evaluation result through the trained curative effect prediction model. The accuracy, the stability and the clinical interpretability of curative effect evaluation are improved.

The invention provides a neutrophil differentiation trajectory inference method and system, and relates to the technical field of cell differentiation trajectory analys.The neutrophil differentiation trajectory inference method comprises the following steps that gene expression data of neutrophil are obtained, and feature selection processing is conducted on the gene expression data of the neutrophil; performing feature mapping processing on the gene expression data set based on a deep learning method; evaluating scores of the alternative models by using a Bayesian information criterion, and screening the alternative model with the highest score as an optimal causal model according to a scoring result; and constructing a differentiation trajectory network according to the causal relationship network in the optimal model, and performing differentiation trajectory inference on the neutrophile granulocytes according to the differentiation trajectory network to obtain a prediction result of the neutrophile granulocyte differentiation trajectory. According to the method, the prediction result of the neutrophil differentiation trajectory can be obtained, and the dynamic process and regulation mechanism of neutrophil differentiation can be disclosed.

The present invention discloses an enhanced tumor vaccine adjuvant, and specifically relates to the field of vaccine adjuvants, the adjuvant comprising granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-9 (IL-9), gamma interferon (IFN-γ) and at least one additional immunomodulatory factor, wherein the immunomodulatory factor is selected from tumor-specific antigen WT1, CD40 ligand (CD40L), Toll-like receptor agonist or a combination thereof. The tumor vaccine adjuvant of the present invention can enhance the body's immune response to the tumor vaccine and improve the prevention and treatment effect of the tumor vaccine on tumors.

The antibody disclosed by the invention can specifically target high-virulence klebsiella pneumoniae of different serotypes, and specifically targets klebsiella pneumoniae of K1 and K2 serotypes. The antibody disclosed by the invention can be combined with high-toxicity klebsiella pneumoniae extracellular capsular polysaccharide with high affinity, has very strong neutralizing activity on klebsiella pneumoniae, and can mediate complement and mature neutrophil to neutralize and kill bacteria in an in-vitro killing experiment, so that the bacterial density is reduced, and the killing effect is improved. The traditional Chinese medicine composition can effectively prevent and treat high-toxicity klebsiella pneumoniae clinical infection and effectively improve pulmonary infection, provides a way for solving the problems of klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance in preventing, diagnosing and treating klebsiella pneumoniae infection, and has important value in development of a new generation of klebsiella pneumoniae medicine.

The invention relates to an antibody composition, a kit and a system for rapidly screening acute promyelocytic leukemia. The antibody composition comprises a first group of antibodies, a second group of antibodies and a third group of antibodies, the first group of antibodies comprises a CD71 antibody, a CD33 antibody, a CD117 antibody, a CD34 antibody, an HLA-DR antibody, a CD19 antibody, a CD10 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises a CD38 antibody, a CD56 antibody, a CD16 antibody, a CD34 antibody, a CD13 antibody, a CD11b antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; the third group of antibodies comprises a CD9 antibody, an MPO antibody, a CD117 antibody and a CD45 antibody; and each antibody is a monoclonal antibody marked with a detection marker. The antibody composition comprises a CD117 + CD33 + region as a main target cell population, and covers three groups of antibodies for identifying acute promyelocytic leukemia, such as CD33, CD34, CD64, CD13, CD9 and MPO, the acute promyelocytic leukemia can be rapidly, simply and conveniently detected by adopting the antibody composition, the detection sensitivity is high, the specificity is high, the accuracy rate is high, and the antibody composition can be widely applied to detection of acute promyelocytic leukemia. The acute promyelocytic leukemia patient can be accurately and quickly identified, and early diagnosis and early treatment are realized.

The invention provides an anti-inflammatory and anti-vascular bidirectional trapping combined self-luminous power compound based on neutrophil nano-vesicles as well as a preparation method and application thereof, and belongs to the technical field of biological medicine manufacturing. The compound takes a neutrophil nano-vesicle as a carrier, and is also loaded with bis (2, 4, 5-trichlorosalicylic acid n-amyl ester) oxalate (CPPO) and a photosensitizer Ce6, and meanwhile, the surface of the compound is modified with ranibizumab through ketal mercaptan responded by ROS (reactive oxygen species). The compound has the characteristics of trapping anti-inflammatory factors and spontaneously targeting corneal neovascularization diseased regions, Ranibizumab is responsively released on the basis of ROS to be combined with vascular endothelial growth factors, the anti-angiogenesis function is achieved, meanwhile, chemical energy generated by CPPO under the high-oxygen condition stimulates Ce6 to generate singlet oxygen, and therefore the vascular endothelial cell tubulogenesis capacity is inhibited. The invention provides a new means for treatment of eye disease related diseases.

The invention relates to the technical field of plant extracts, and provides a plant extract composition with synergistic hypoglycemic activity and application thereof, and the plant extract composition comprises a mulberry leaf extract, a white kidney bean extract and bitter gourd powder in a mass ratio of 8: (1-24): (1-64). By optimizing the mass ratio of the mulberry leaf extract, the white kidney bean extract and the bitter gourd powder, the blood sugar reducing effect of the plant extract taking the mulberry leaf extract, the white kidney bean extract and the bitter gourd powder as main raw materials is remarkably superior to that of a plant extract in the prior art. Meanwhile, the plant extract composition also has the effects of synergistically reducing the number of neutrophils around nerves, improving peripheral neuroinflammation, synergistically enhancing the fluorescence intensity of the peripheral nerves, improving peripheral nerve injury and inhibiting the enzymatic activity of a bacterium source dipeptidyl peptidase-4.

The present disclosure relates to methods of treating a subject suffering from an eosinophil-associated chronic obstructive pulmonary disease (COPD) or asthma-COPD overlap (ACO) using compounds that bind to CD131 and inhibit signalling of interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF).

The invention relates to the technical field of artificial intelligence, in particular to a special child disease classification method based on particle-ball cross-granularity knowledge collaborative feature selection. The method comprises the following steps: firstly, providing a cross-granularity knowledge collaboration method based on granules and balls; further designing a fuzzy rough set model based on particle-ball cross-granularity knowledge collaboration to perform feature selection; according to the method, feature knowledge under different granularity levels is mined and coordinated to realize more robust and more efficient feature selection, so that the accuracy, generalization ability and interpretability of a classification model are improved, and a more reliable technical tool is provided for early screening and auxiliary diagnosis of diseases of special children.

The invention relates to the technical field of general image data processing or generation, in particular to a multi-view indirect immunofluorescence medical image classification interpretation method and system, and the method comprises the steps: mapping an ethanol view, a formaldehyde view and an HEp-2 view to a feature space, and converting into a feature sequence; performing position coding on the feature sequence to obtain position information; based on the feature sequence with the position information, modal identification information is added, and an identification feature sequence is determined; based on the identification feature sequence, executing multi-modal information fusion, and determining a multi-modal feature sequence; based on the multi-modal feature sequence, combining an attention mechanism to determine a long-distance dependency relationship and correlation between the data; and based on the attention mechanism model, outputting the probability of each category to execute classification interpretation. According to the method, the type of the anti-neutrophil cytoplasm antibody fluorescence model can be adaptively and comprehensively judged in combination with the characteristics of fluorescence brightness, forms and the like of different views, and interference existing in a single view is avoided.

The invention discloses lactobacillus paracasei CFCFC018, a microbial agent and application of the lactobacillus paracasei CFCFC018, and belongs to the technical field of microorganisms. The lactobacillus paracasei CFCFC018 is separated from intestinal contents of rural cats in half-farming and half-pastoral areas in Inner Mongolia, does not need genetic engineering modification, can highly express amino acids and neurotransmitters, can remarkably relieve mammary gland alveolar structure damage in mammary gland tissues of rats suffering from mastitis induced by staphylococcus aureus, and has the advantages of being high in safety and good in stability. The thickening of a mammary gland interacellular matrix layer is avoided, the infiltration number of neutrophils is reduced, the damage degree of mammary gland tissues is reduced, and a certain protection effect on the mammary gland tissues is achieved. The research also shows that the strain can reduce the abundance of harmful bacteria in excrement, improve intestinal inflammation and relieve edema of intestinal submucosa, which provides a new thought for preventing and treating mastitis by regulating intestinal microbiota.

The invention discloses a core-shell microneedle for removing bacterial biofilms and a preparation method of the core-shell microneedle, and belongs to the technical field of biological medicines. The core-shell microneedle comprises a shell layer and a core layer, the shell layer comprises a shell layer material and copper peroxide nanoparticles loaded on the shell layer material, and the core layer comprises a core layer material and mesoporous polydopamine nanoparticles loaded on the core layer material, coated with citraconate and capable of targeting neutrophils. The biofilm can penetrate through a biofilm and preferentially release copper peroxide nanoparticles, the oxidation-reduction steady state in the biofilm is destroyed, bacteria are killed, and the biofilm is dispersed; the polypeptide can target neutrophil, relieve the immunosuppression state of congenital immune cells and recover the bacterial killing ability of the congenital immune cells, so that escaped bacteria are effectively phagocytized; through the synergistic effect of the two, the biological membrane can be completely removed, the biological membrane removing agent has a clinical application prospect, and bacterial drug resistance caused by long-term use of antibiotics is reduced.

Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

The invention relates to the technical field of hepatic failure treatment, and particularly discloses application of tsRNA-20 or a simulant thereof in preparation of drugs for treating chronic plus acute hepatic failure and / or promoting liver cell proliferation. Through tsRNA sequencing and qRT-PCR verification, down-regulated expression of the tsRNA-20 in a plasma sample and liver tissue in chronic and acute hepatic failure is determined, and cell experiments find that the tsRNA-20 regulates an ACPH / GRHL1 axis to promote liver cell proliferation. Specifically, it is found that tsRNA-20 is combined with an amidyl peptide hydrolase (ACPH), so that a Ras-ERK pathway is activated, nuclear translocation of a granulocyte-like transcription factor 1 (GRHL1) is promoted, and finally liver cell proliferation is enhanced. Therefore, when the tsRNA-20, the precursor tRNA-GIy-CCC thereof and the regulated objects ACPH and GRHL1 thereof are applied to treatment of the chronic and acute liver failure, the tsRNA-20, the precursor tRNA-GIy-CCC thereof and the regulated objects ACPH and GRHL1 thereof can be used as targets to be regulated to promote liver cell proliferation, so that liver regeneration is promoted, the treatment effect of the chronic and acute liver failure is improved, the lifetime of patients with liver diseases is prolonged, and the tsRNA-20, the precursor tRNA-GIy-CCC and the regulated objects ACPH and GRHL1 possibly become new targets for precise treatment. The clinical application value is relatively high.

The invention discloses siRNA (small interfering Ribonucleic Acid) nanoparticles capable of efficiently targeting mononuclear phagocytes and mediated by intercellular effect of neutrophils as well as a preparation method and application of the siRNA nanoparticles. The siRNA nanoparticles comprise mesoporous silica nanoparticles carrying siRNA, and functional cell membranes over-expressing ICAM-1 ligands are wrapped outside the mesoporous silica nanoparticles carrying siRNA. Key sentinel cells (mononuclear phagocytes, MPs) for targeted mitochondrial DNA release to treat inflammatory responses caused by mtDNA. The efficient delivery of MPs is realized by using a functionalized cell membrane of an overexpressed ICAM-1 ligand to wrap nano-particles and by virtue of infiltration and rapid apoptosis of a large number of neutrophils in an inflammatory microenvironment and a process (cell burial effect) of specific phagocytosis of the neutrophils by the MPs. Compared with a traditional targeting scheme, the in-vitro targeting efficiency and the in-vivo targeting efficiency of the FCM-coated siNPs scheme are improved by 360% and 120% respectively. The siRNA is guided to target MPs, and the expression of STING is inhibited, so that the inflammatory reaction caused by mtDNA release is regulated and controlled, and an excellent anti-inflammatory curative effect is shown in an inflammatory model mouse.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38′ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and / or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

The invention discloses a blood routine examination and immunochromatography combined detection reagent card, and belongs to the technical field of medical detection, the blood routine examination and immunochromatography combined detection reagent card comprises a reagent card body, the reagent card body comprises a detection counting area, a reagent liquid filling area and a sampling area, the sampling area is used for accommodating a sample and pre-diluting the sample, the reagent liquid filling area is used for treating and diluting the sample, and the detection counting area is used for counting the detection counting area. The detection counting area comprises a red blood cell counting square groove, a white blood cell counting square groove and a blood platelet counting square groove. Five groups of neutrophil, lymphocyte, mononuclear cell, eosinophilic granulocyte and basophilic granulocyte in leukocyte are realized, and promotion of a basic POCT instrument can be promoted by matching with other necessary blood routine parameters and CRP, SAA, glycosylated hemoglobin and other parameters. The operation of a user is convenient, the joint detection test of blood routine examination and immunochromatography items can be fully automatically completed by one reagent card and the immunochromatography card, and extra dilution of a sample is not needed.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

To provide methods for managing, treating, or preventing an eosinophil or mast cell related disorder and / or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).SOLUTION: The present invention provides a method including administering to a subject in need thereof a therapeutically effective amount of an antibody which specifically binds to a KIT receptor tyrosine kinase.SELECTED DRAWING: None

The present invention relates to a method, in particular an in vitro method, for identifying an improved anti-senescence compound based on detecting the binding of said compound in the presence of at least one phosphory lated amino acid in the transcription activation domain (TAD) domain of mammalian protein p53. The present invention further relates to a method, in particular an in vitro method, for monitoring an anti-senescence treatment or prophylaxis in a mammalian subject in need thereof, based on detecting the amount of phosphorylation of amino acids in the TAD and / or C-terminal region of the mammalian p53 protein in a biological sample obtained from said subject and / or detecting the amount and / or co-localization with phosphorylated p53 of the promyelocytic leukemia protein (PML) bodies in a biological sample obtained from said subject. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof. Finally, improved anti-senescence compounds or pharmaceutical compositions are provided.

This invention relates to the fields of biomedical technology and biological model construction technology, and discloses an ANCA-associated vasculitis glomerular endothelial cell injury model, its construction method and application, and the application of BACH1 inhibitors. The method includes: (1) activating neutrophils sequentially with tumor necrosis factor α and immunoglobulin G to obtain a culture medium containing activated neutrophils; wherein the immunoglobulin G is immunoglobulin G isolated and purified from the plasma of patients with ANCA-associated vasculitis; (2) co-culturing the culture medium containing activated neutrophils with human glomerular endothelial cells to obtain the cell injury model. The cell injury model provided by this invention can verify the role of neutrophil adhesion characteristics in endothelial cell injury, and at the same time, the cell injury model can better simulate the immune microenvironment of ANCA-associated vasculitis glomerular endothelial cells in vivo.

The invention discloses a traditional Chinese medicine prescription for treating myelosuppression after chemotherapy as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine prescription is prepared from ten traditional Chinese medicines including caulis spatholobi, flos caryophylli, astragalus membranaceus, rhizoma cimicifugae, sanguisorba officinalis, hairyvein agrimony, rhodiola rosea, codonopsis pilosula, cinnamon and angelica sinensis, and has the effect of obviously improving myelosuppression after chemotherapy. Meanwhile, the traditional Chinese medicine composition has good curative effects on four types of myelosuppression after chemotherapy, including leucopenia, neutropenia, thrombocytopenia and over-low hemoglobin. The prescription is good in stability, high in safety and remarkable in curative effect.

The invention discloses an auxiliary medical diagnosis method based on pellet Markov random walk, and belongs to the technical field of medical data analysis, and the method comprises the steps: carrying out the standardization processing of medical data, and obtaining the data after the standardization processing; self-adaptively generating different sizes of pellets to cover the sample space, and calculating the center and radius of each pellet; calculating the distance between the pellets, and constructing a state transition matrix based on the pellets; generating steady-state distribution through iterative calculation, and normalizing the steady-state distribution into the abnormal degree of each pellet; calculating an anomaly score of each sample by associating the anomaly degree of each pellet with the sample covered by the pellet; and judging whether the abnormal scores of the samples are greater than a threshold value one by one, if so, outputting abnormal points of the medical data, otherwise, regarding the data as normal data until all the samples are judged. According to the method, the problem that multi-granularity abnormal information in medical data is difficult to mine by an existing abnormal detection method is solved, so that auxiliary medical diagnosis is more effectively realized.

The present disclosure relates to a method for reducing or hindering development of renal ischemia-reperfusion injury in a subject the method comprising administering an antibody that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation.

The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.

Embodiments of the instant disclosure relate to intervention and / or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

The present application provides antibodies including antigen-binding fragment thereof that specifically recognizing Granulocyte-Macrophage Colony Stimulating Factor Receptor (GM-CSFRα). Also provided are methods of making and using these antibodies.